ArticlePsychiatry investigation2018
The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology
Article in Psychiatry investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Childhood abuse moderates the impact of serum BDNF on short- and long-term antidepressant response.European child & adolescent psychiatry · 2026Article
- Sex-specific Serum Biomarker Associations with Antidepressant Treatment Outcomes in Depressive Disorders.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Article
- Prediction of 12-Week Remission in Patients With Depressive Disorder Using Reasoning-Based Large Language Models: Model Development and Validation Study.JMIR mental health · 2026Article
- Interactive dynamic modulation of antidepressant treatment response by serum interleukin-1β and Neuroticism at 12 weeks.Scientific reports · 2026Article
- Clinical Outcomes and Treatment Intensification across Depression Subtypes in Patients Receiving Stepwise Pharmacotherapy over 24 Months.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025Article
- Functional status modifies the impact of tumor necrosis factor-alpha on depression treatment response.BJPsych open · 2025Article
- Prospective Associations of Serum Tumor Necrosis Factor-Alpha and Employment on Suicidal Behaviors Over 1 Year in Depressive Patients Receiving Psychopharmacotherapy.Psychiatry investigation · 2025Article
- Interplay between Stressful Life Events and Interleukin-1β on 12-week Antidepressant Response in Depressive Patients.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025Article
- Employment-dependent associations of serum biomarkers with short- and long-term antidepressant treatment outcomes.Frontiers in psychiatry · 2025Article
- Interaction Effect of Childhood Abuse History and Suicidality on 12-Month Antidepressant Response in Patients With Depressive Disorder.Psychiatry investigation · 2024Article
- Use of Serum Biomarkers to Aid Antidepressant Selection in Depressive Patients.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Article
- Age-specific associations between serum cholesterol levels and suicidal behaviors in patients with depressive disorders: A naturalistic prospective observational cohort study.Frontiers in psychiatry · 2023Article
- Editorial: Biomarkers of mental well-being continuum across life span: from excelling to crisis.Frontiers in pharmacology · 2023Article
- Interaction effect between childhood abuse and interleukin-1β levels on suicidality in depressed patients.European archives of psychiatry and clinical neuroscience · 2022Article
- Interactive Effects of Serum Leptin Levels and Physical Comorbidity on the Pharmacotherapeutic Response of Depressive Disorders.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Article
- Prediction of 12-Week Remission by Psychopharmacological Treatment Step in Patients With Depressive Disorders.Psychiatry investigation · 2022Article
- Associations of Serum Serotonin Levels with 12-week and 12-month Remission in Patients with Depressive Disorders.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Article
- Childhood Abuse, Social Support, and Long-Term Pharmacological Treatment Outcomes in Patients With Depressive Disorders.Frontiers in psychiatry · 2022Article
- Interaction effect of serum serotonin level and age on the 12-week pharmacotherapeutic response in patients with depressive disorders.Scientific reports · 2021Article
- Predictive values of tumor necrosis factor-α for depression treatment outcomes: effect modification by hazardous alcohol consumption.Translational psychiatry · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveDepression is associated with a major disease burden, and many individuals suffer from depressive symptoms due to an insufficient response to ostensibly adequate antidepressant treatment. Therefore, it is important to identify reliable treatment response predictors for use in developing personalized treatment strategies.
methodsThe MAKE Biomarker discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) study was performed to identify predictors of antidepressant response using a 2-year naturalistic prospective design. Participants in the MAKE BETTER study were consecutively recruited from patients who visited the Psychiatry Department of Chonnam National University Hospital, Gwangju, South Korea for treatment of a depressive disorder. Data on demographic and clinical characteristics, genetic markers measured by whole-exome sequencing, and blood markers were obtained. The types and doses of antidepressants were determined based on the clinical judgment of the psychiatrist, and the treatment outcomes (e.g., depressive and other psychiatric symptoms and issues related to safety) were assessed.
resultsWe will be able to use the data collected in this study to develop a treatment-response prediction index composed of biomarkers.
conclusionThe MAKE BETTER study will provide an empirical basis for a personalized medicine approach to depression by enabling the prediction of antidepressant treatment response according the characteristics of each patient. It will thereby support evidence-based decision-making that decreases the use of a trial-and-error approach to the treatment of depressive disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.